Ypsomed Holding AG stock analysis
Ypsomed Holding AG (0QLQ) Share Price & Analysis
0QLQ Stock Chart & Stats
- Day’s Range
- CHF 421.80 - CHF 428.00
- 52-Week Range
- CHF 263.50 - CHF 437.20
- Previous Close
- CHF 429.40
- Volume
- N/A
- Average Volume (3M)
- 881
- Market Cap
- CHF 5.54B
- Enterprise Value
- CHF 5.12B
- Total Cash (Recent Filing)
- CHF 37.17M
- Total Debt (Recent Filing)
- CHF 337.31M
- Price to Earnings (P/E)
- 33.4
- Beta
- 0.87
- Next Earnings
- May 26, 2027 (Est.)
- EPS Estimate
- 8.64
- Last Dividend Ex-Date
- Jul 03, 2026
- Dividend Yield
- 1.04%
Bulls Say, Bears Say
Bulls Say
Autoinjector-led Market Position And Growth
Ypsomed’s strong autoinjector position supports durable growth because its platforms are embedded in a broad range of pharmaceutical programs. The combination of high current exposure, customer adoption and recurring commercialization opportunities should reinforce competitive relevance over the next several quarters.
Expanding Customer And Product Pipeline
A broad, expanding pipeline diversifies future revenue beyond individual products or customers and creates multiple paths to commercialization. New projects, therapeutic applications and customer wins can translate into longer-term device supply opportunities as programs advance through clinical and commercial stages.
Strong Profitability And Operating Cash Generation
Material improvement in earnings and operating cash generation demonstrates stronger underlying economics and gives Ypsomed greater capacity to fund expansion. High profitability can support continued innovation, capacity investment and balance-sheet resilience while the business scales its delivery-system platforms.
Bears Say
Persistent Negative Free Cash Flow
Sustained negative free cash flow means strong operating earnings are not yet converting fully into discretionary cash. Continued investment or working-capital demands could constrain internal funding, increase reliance on financing and reduce flexibility if growth projects take longer to mature.
Heavy Capacity Investment Cycle
The elevated investment program creates execution and returns risk over the next two to six months, as new capacity must ramp efficiently to absorb its cost. Until spending declines and facilities contribute meaningfully, cash conversion and near-term financial flexibility are likely to remain pressured.
Near-term Margin Pressure And Contract Phase-outs
Capacity ramp costs, volume-based pricing and the loss of Sanofi manufacturing revenue may weigh on profitability even as sales grow. These factors can dilute mix and margins during the transition, requiring successful execution and new volume wins to preserve the company’s earnings trajectory.
0QLQ FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
What is Ypsomed Holding AG’s market cap?
When is Ypsomed Holding AG’s upcoming earnings report date?
How were Ypsomed Holding AG’s earnings last quarter?
Is Ypsomed Holding AG overvalued?
Does Ypsomed Holding AG pay dividends?
What is Ypsomed Holding AG’s EPS estimate?
How many shares outstanding does Ypsomed Holding AG have?
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ypsomed Holding AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
- Sector
- General
- Industry
- Medical - Specialties
- CEO
- Simon Michel
- Employees
- 2,025
- Website
- www.ypsomed.com
- Address
- Brunnmattstrasse 6, Burgdorf, BE, 3401, CH
Ypsomed Holding AG (0QLQ) Earnings & Revenues
0QLQ Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Ypsomed reported robust first-half growth, record revenue and EBIT, significant new customer and project wins, strong autoinjector momentum, and raised full-year guidance. The company also confirmed its midterm targets and described substantial innovation and capacity expansion. These positives outweighed the negative free cash flow, elevated investment cycle, Other-segment losses, contract-manufacturing phase-outs and expected near-term margin pressure.
View all GB:0QLQ earnings summaries0QLQ Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 3 | 6 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 10 | 0 | 2 |







